7910 Woodmont Avenue,Suite 1210
Bethesda, Maryland 20814, U.S.A. 
info@mlsvfund.com |   +1 301 298 5455

© 2018  by MASA Life Science Ventures, LP

Apellis Reports Positive Top-line Results from Phase 3 Head-to-Head Study of Pegcetacoplan (APL-2) Compared to Eculizumab in Patients with Paroxysmal...

January 7, 2020

Please reload

Featured Posts

Potentia Pharmaceuticals Awarded Phase I STTR Grants from the National Eye Institute

June 1, 2006

Louisville, Ky. – Potentia Pharmaceuticals, together with academic collaborators, received two Phase I STTR grants from the National Eye Institute to develop new, less invasive delivery technologies for ocular therapeutics. The first grant, involving a collaboration with the Lions Eye Center of the University of Louisville, investigates the use of disease-targeted polymeric nanoparticles that could be administered intravenously. The second program will explore the use of a local controlled-release transscleral delivery vehicle in collaboration with the University of Arkansas for Medical Sciences. These two programs address the important aspect of delivery of drugs to the back of the eye, one of the major obstacles currently facing many promising therapies for ocular diseases.



Please reload